MXPA05006072A - Usos de carnitinas para prevencion y/o tratamiento de trastornos provocados por la andropausia. - Google Patents

Usos de carnitinas para prevencion y/o tratamiento de trastornos provocados por la andropausia.

Info

Publication number
MXPA05006072A
MXPA05006072A MXPA05006072A MXPA05006072A MXPA05006072A MX PA05006072 A MXPA05006072 A MX PA05006072A MX PA05006072 A MXPA05006072 A MX PA05006072A MX PA05006072 A MXPA05006072 A MX PA05006072A MX PA05006072 A MXPA05006072 A MX PA05006072A
Authority
MX
Mexico
Prior art keywords
prevention
treatment
andropause
carnitines
disorders caused
Prior art date
Application number
MXPA05006072A
Other languages
English (en)
Spanish (es)
Inventor
Biagiotti Giulio
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of MXPA05006072A publication Critical patent/MXPA05006072A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Pregnancy & Childbirth (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MXPA05006072A 2002-12-13 2003-11-20 Usos de carnitinas para prevencion y/o tratamiento de trastornos provocados por la andropausia. MXPA05006072A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000620A ITRM20020620A1 (it) 2002-12-13 2002-12-13 Uso delle carnitine per la prevenzione e/o il trattamento dei disturbi causati dall'andropausa.
PCT/IT2003/000757 WO2004054567A1 (en) 2002-12-13 2003-11-20 Use of carnitines for the prevention and/or treatment of disorders caused by the andropause

Publications (1)

Publication Number Publication Date
MXPA05006072A true MXPA05006072A (es) 2005-09-30

Family

ID=32587900

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05006072A MXPA05006072A (es) 2002-12-13 2003-11-20 Usos de carnitinas para prevencion y/o tratamiento de trastornos provocados por la andropausia.

Country Status (17)

Country Link
US (1) US7956091B2 (enExample)
EP (1) EP1569635B1 (enExample)
JP (1) JP4767542B2 (enExample)
KR (1) KR101039818B1 (enExample)
AT (1) ATE422883T1 (enExample)
AU (1) AU2003288739A1 (enExample)
CA (1) CA2507429C (enExample)
CY (1) CY1109051T1 (enExample)
DE (1) DE60326262D1 (enExample)
DK (1) DK1569635T3 (enExample)
ES (1) ES2322455T3 (enExample)
IT (1) ITRM20020620A1 (enExample)
MX (1) MXPA05006072A (enExample)
PL (1) PL211032B1 (enExample)
PT (1) PT1569635E (enExample)
SI (1) SI1569635T1 (enExample)
WO (1) WO2004054567A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272812A1 (en) * 2002-02-07 2005-12-08 Pettegrew Jay W Methor for use of acetyl-L-carnitine (ALCAR) for treatment of depressive disorders in humans
US7407778B2 (en) 2002-02-07 2008-08-05 Pettegrew Jay W Compounds, compositions and methods for treating neuropsychiatric disorders
US7700074B2 (en) 2002-02-07 2010-04-20 Pettegrew Jay W Method and system for diagnosis of neuropsychiatric disorders including chronic alcoholism
EP1641806B1 (en) 2003-05-29 2009-07-29 Jay W. Pettegrew Glycerophosphocholine and its derivatives for medical imaging of neuropsychiatric disorders
ITRM20040561A1 (it) * 2004-11-11 2005-02-11 Sigma Tau Ind Farmaceuti Uso della acetil l-carnitina in combinazione con propionil l-carnitina e sildenafil per il trattamento della disfunzione erettile.
KR101460125B1 (ko) * 2013-02-05 2014-11-11 주식회사 바이오그랜드 루이보스 추출물을 유효성분으로 하는 남성 노화 및 갱년기 예방 및 개선용 조성물
WO2016167254A1 (ja) * 2015-04-17 2016-10-20 株式会社山田養蜂場本社 蜂の子を含有する滋養強壮剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3830931A (en) * 1972-11-06 1974-08-20 Felice S De Carnitine and its use in the treatment of arrhythmia and impaired cardiac function
IT1206954B (it) * 1979-02-12 1989-05-17 Sigma Tau Ind Farmaceuti Agenti terapeutici a base di un acil derivato della carnitina per la cura di vasculopatie periferiche
IT1116037B (it) * 1979-04-23 1986-02-10 Sigma Tau Ind Farmaceuti Esteri e ammidi di acil carnitine loro procedimenti di preparazione e loro uso terapeutico
IT1157238B (it) * 1982-10-29 1987-02-11 Sigma Tau Ind Farmaceuti Impiego di 1-carnitina per migliorare i paramenti biochimici e comportamentali dell'eta' senile
EP0681839A3 (en) 1994-05-12 1997-11-12 Hirohiko Kuratsune A pharmaceutical preparation comprising an acylcarnitine
IT1290801B1 (it) * 1996-07-05 1998-12-11 Mendes Srl Uso della acetil l-carnitina, della isovaleril l-carnitina, della propionil l-carnitina o dei loro sali farmacologicamente accettabili
IT1291127B1 (it) * 1997-04-01 1998-12-29 Sigma Tau Ind Farmaceuti Integratore alimentare per soggetti dediti ad intensa e prolungata attivita' fisica
IT1295408B1 (it) * 1997-10-03 1999-05-12 Sigma Tau Ind Farmaceuti Associazione di l-carnitina e alcanoil l-carnitine per il trattamento dell'alcoolismo
IT1302125B1 (it) * 1998-08-03 2000-07-31 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante ed antiproliferativacomprendente una carnitina ed un carotenoide
IT1302307B1 (it) * 1998-09-01 2000-09-05 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante ed atta a migliorarel'utilizzazione metabolica del glucosio, comprendente acetil
IT1306130B1 (it) * 1999-04-16 2001-05-30 Sigma Tau Healthscience Spa Composizione comprendente una carnitina e glutatione, atta adaumentare l'assorbimento del glutatione sinergizzandone gli effetti.
US6399116B1 (en) * 2000-04-28 2002-06-04 Rulin Xiu Rhodiola and used thereof
DE60216090T2 (de) * 2001-05-29 2007-05-31 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Verwendung von l-acetylcarnitin zur herstellung eines medikaments zur behandlung von anhedonia

Also Published As

Publication number Publication date
PT1569635E (pt) 2009-05-11
JP2006511531A (ja) 2006-04-06
US20060135606A1 (en) 2006-06-22
CA2507429C (en) 2012-09-04
KR20050084052A (ko) 2005-08-26
ITRM20020620A1 (it) 2004-06-14
ES2322455T3 (es) 2009-06-22
DK1569635T3 (da) 2009-04-20
CA2507429A1 (en) 2004-07-01
EP1569635A1 (en) 2005-09-07
EP1569635B1 (en) 2009-02-18
ATE422883T1 (de) 2009-03-15
AU2003288739A1 (en) 2004-07-09
SI1569635T1 (sl) 2009-06-30
WO2004054567A1 (en) 2004-07-01
PL211032B1 (pl) 2012-04-30
US7956091B2 (en) 2011-06-07
JP4767542B2 (ja) 2011-09-07
PL378418A1 (pl) 2006-04-03
KR101039818B1 (ko) 2011-06-09
DE60326262D1 (de) 2009-04-02
CY1109051T1 (el) 2014-07-02

Similar Documents

Publication Publication Date Title
CA2341973A1 (en) Antioxidant composition comprising acetyl l-carnitine and .alpha.-lipoic acid
CY1109051T1 (el) Χρηση καρνιτινων για την προληψη και/ή θεραπεια διαταραχων που προκαλουνται απο την ανδροπαυση
FI3457135T3 (fi) Fabryn taudin hoitovaihtoehtoja
TW200744574A (en) Use of L-carnitine or of alkanoyl L-carnitines for the preparation of a physiological supplement of medicament for ophthalmic use in the form of eye-drops
MXPA05003732A (es) Metodos y composiciones para proporcionar glutamina.
IT1295408B1 (it) Associazione di l-carnitina e alcanoil l-carnitine per il trattamento dell'alcoolismo
EP1509220A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF SEBORRHEA CONTAINING 4-HYDROXY-5-METHOXY-4- 2-METHYL-3- (3-METHYL-2-BUTENYL) -2-OXIRANYL -1-OXASPIRO 2,5 OCTANE-6-ONE
AR021172A1 (es) Composicion antiprolifica, antioxidante, que comprende una carnitina y un carotenoide
CY1111273T1 (el) Συνδυασμενη χρηση της l-καρνιτινης, ακετυλο l-καρνιτινης και προπιονυλο l-καρνιτινης για τη θεραπεια της ολιγοασθενοτερατοσπερμιας
SG162836A1 (en) Use of a combination comprising l-carnitine or alkanoyl l-carnitine, lipid solubl benzoquinone and omega-3-polyunsaturated fatty acid for the preparation of a dietary supplement or medicament for the treatment of corneal diseases
PL378537A1 (pl) Zastosowanie propionylo L-karnityny do otrzymywania leku do leczenia glaukomii
WO2001007039A3 (en) L-acetylcarnitine and l-propionylcarnitine containing composition for the prevention and treatment of kidney dysfunctions and diseases
PL1824472T3 (pl) Zastosowanie acetylo-L-karnityny do wytwarzania leku do leczenia zespołu fibromialgii
PL1937245T3 (pl) Związek użyteczny w zapobieganiu i leczeniu przerostu lewej komory u pacjentów dializowanych
PL367616A1 (en) Use of acetyl l-carnitine for the preparation of a medication for the preventive therapy for pain
IL164763A0 (en) Byperforin derivatives, the use thereof and formulations containing them
TW200420560A (en) Crystalline form
NZ508292A (en) Treatment of migraine symptoms with ibuprofen and salts thereof
Korhonen Dietary treatment of elevated blood pressure
RU2002124697A (ru) Биологически активная добавка "мумивит"
AU2002336725A1 (en) Use of methotrexate and l-arginine for the preparation of a medicament for treatment of uterine myoma
MX9304553A (es) Complejo de ibuprofen-beta-ciclodextrina para la fabricacion de unmedicamento de consumo oral, procedimiento para su preparacion ycomposiciones farmaceuticas que lo contienen.
RU2002125553A (ru) Способ профилактики и лечения гепатодистрофии поросят

Legal Events

Date Code Title Description
FG Grant or registration